Detecting molecular residual disease with Signatera
Design and analytical validation of SignateraTM, the first ctDNA assay custom-built for detecting MRD and assessing treatment response.
Design and analytical validation of Signatera™, the first ctDNA assay custom-built for detecting MRD and assessing treatment response.